Bristol, Merck checkpoint inhibitors focus of FDA advisory committee meeting
Opdivo (nivolumab) and Merck's (NYSE:MRK) Keytruda (pembrolizumab), two highly popular checkpoint inhibitors used in the ...
HealthDay on MSN4d
Adjuvant Pembrolizumab Improves Survival in Muscle-Invasive Urothelial Cancer
Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk ...
Medscape5d
Pembrolizumab Approved With Chemotherapy for Malignant Pleural Mesothelioma
Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...
Medscape7d
Pembrolizumab Plus Chemoradiotherapy Provides Significant Survival Benefit in Cervical Cancer
Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...
emjreviews.com9d
Pembrolizumab with Chemoradiotherapy Improves Cervical Cancer Survival: ESMO 2024
Discover the results from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, presented at ESMO 2024, Barcelona, Spain ...
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult ...
oncnursingnews8d
Perioperative Pembrolizumab Improves Survival in Early-Stage TNBC
Patients with early-stage triple-negative breast cancer tended to have improved survival with neoadjuvant pembrolizumab plus ...
Targeted Oncology7d
KEYNOTE-A18 Supports Pembrolizumab and CRT as New Standard in High-Risk Cervical Cancer
Pembrolizumab combined with chemoradiotherapy followed by pembrolizumab monotherapy significantly improved survival compared ...
MedPage Today on MSN8d
Another Possible Treatment Option for Intermediate-Stage Liver Cancer
Median PFS increased from 10 months with TACE to 14.6 months with the addition of lenvatinib (Lenvima) and pembrolizumab ...
Postsurgical treatment with pembrolizumab doubles cancer-free time for bladder cancer patients
Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free following ...
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...